<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04365803</url>
  </required_header>
  <id_info>
    <org_study_id>IEO 0758/</org_study_id>
    <nct_id>NCT04365803</nct_id>
  </id_info>
  <brief_title>Histology VABB-Histology Post Surgery Pilot Project (BETTY Trial)</brief_title>
  <acronym>BETTY</acronym>
  <official_title>Comparison Between Histological VABB and Histological Post-surgery in Patient With Complete Pathological Response After Neoadjuvant Systemic Treatment: Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Institute of Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Institute of Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot study on patients with invasive ductal breast cancer triple negative or receptor&#xD;
      tyrosine-protein kinase erbB-2 (HER2) overexpressed, any axillary lymphnodes status (any cN),&#xD;
      candidates to neoadjuvant chemotherapy.&#xD;
&#xD;
      The principal endpoint of the study will be the accuracy of the result of the histological&#xD;
      examination of the Vacuum- Assisted Breast Biopsy (VABB) performed pre-surgery in comparison&#xD;
      to the result of the histological examination of the definitive surgical intervention in&#xD;
      patients with radiological complete response at Magnetic resonance imaging (MRI) done after&#xD;
      the end of neoadjuvant chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study articulates in five phases:&#xD;
&#xD;
      Phase one: acquisition of the informed consent followed by positioning a clip into the cancer&#xD;
      bed (by radiologist) if not already present; Phase two: after radiological confirmation of&#xD;
      pathological Complete Response (pCR) done performing breast ultrasound, MRI and&#xD;
      18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose positron emission tomography (18-FDG-PET)&#xD;
      after neoadjuvant chemotherapy the patient becomes candidate to VABB pre surgery.&#xD;
&#xD;
      Phase three: the patient has VABB within 15 day from the term of neoadjuvant chemotherapy&#xD;
      Phase four: definitive surgical intervention within 30 days from the end of the neoadjuvant&#xD;
      chemotherapy Phase five: verification of correspondence between histology of VABB and&#xD;
      definitive histology.&#xD;
&#xD;
      The study hypothesis is that VABB could be used in the patients with pCR to the imaging&#xD;
      post-neoadjuvant chemotherapy to confirm sensibility and specificity of 18 FDG TC PET and&#xD;
      breast MRI to show the absence of breast cancer.&#xD;
&#xD;
      The use of VABB with negative histology result could bring to a therapeutic gold standard&#xD;
      without over surgical treatment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the accuracy of histological examination of the VABB performed pre-surgery</measure>
    <time_frame>45 days</time_frame>
    <description>Identification of percentage of cases with correspondence between histology of VABB presurgery and histology of definitive surgery in patients with complete radiological response after neoadjuvant chemotherapy</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>patient with radiological complete response</arm_group_label>
    <description>patient with radiological complete response after neoadjuvant chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>vacuum-assisted breast biopsy</intervention_name>
    <description>patient with radiological complete response after neoadjuvant chemotherapy undergo to vacuum assisted breast biopsy and the to definitive surgery</description>
    <arm_group_label>patient with radiological complete response</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with triple negative or HER2 over-expressed breast cancer with radiological&#xD;
        complete response after neoadjuvant chemotherapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age â‰¥ 18 aa;&#xD;
&#xD;
          -  histological diagnosis done at European Institute of Oncology (if not, to does&#xD;
             revision of pathological material);&#xD;
&#xD;
          -  invasive ductal breast cancer triple negative or HER2 overexpressed, any cN;&#xD;
&#xD;
          -  neoadjuvant standard systemic treatment after surgery +/- trastuzumab;&#xD;
&#xD;
          -  propose of conservative or demolitive surgery;&#xD;
&#xD;
          -  M0&#xD;
&#xD;
          -  cancer bed identified pre neoadjuvant chemotherapy by clip&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  multicentric or bilateral breast cancer&#xD;
&#xD;
          -  mammography microcalcifications&#xD;
&#xD;
          -  in situ breast carcinoma&#xD;
&#xD;
          -  positive anamnesis for previous breast cancer&#xD;
&#xD;
          -  positive anamnesis for medical or psychological conditions that prevent membership&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisabetta Rossi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>European Institute of Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>European Instituto of Oncology</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 24, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2020</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast cancer</keyword>
  <keyword>vacuum assisted breast biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

